Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Neurodegenerative disease.

¹Neurology Research, Massachusetts General Hospital, Harvard Medical School, Warren 408, Boston, MA 02114, USA. browne@helix.mgh.harvard.edu

Idrugs : the Investigational Drugs Journal

|September 24, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Faith versus Fear.

The Journal of the College of General Practitioners·2009

Same author

Migraine Symposium.

The Journal of the College of General Practitioners·2009

Same author

Buscopan.

The Journal of the College of General Practitioners·2009

Same author

Hypnosis in a GP obstetric unit.

The practising midwife·2009

Same author

High risk pregnancy in the workplace. Influencing positive outcomes.

AAOHN journal : official journal of the American Association of Occupational Health Nurses·2002

Same author

N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.

Journal of neurochemistry·2001

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

This report focuses on cell death mechanisms in neurodegenerative diseases like Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). It highlights key research findings presented at the Society of Neuroscience meeting.

Area of Science:

Neuroscience
Cell Biology
Pathology

Background:

Neurodegenerative diseases, including Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD), are characterized by progressive neuronal dysfunction and death.
Understanding the underlying mechanisms of cell death is crucial for developing effective therapeutic strategies.

Purpose of the Study:

To summarize key research findings on cell death mechanisms in neurodegenerative diseases presented at the Society of Neuroscience meeting.
To focus on Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD) as specific examples.

Main Methods:

The report is based on a selection of presentations from the Society of Neuroscience meeting.
The selection criteria focused on the reporter's research interests in cell death mechanisms.

Related Experiment Videos

Main Results:

Presentations covered various aspects of cell death pathways relevant to HD, ALS, and PD.
Specific molecular and cellular mechanisms contributing to neurodegeneration were discussed.

Conclusions:

Further research into cell death mechanisms is essential for advancing treatments for neurodegenerative diseases.
The Society of Neuroscience meeting provided valuable insights into ongoing research in this field.